Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor α

New England Journal of Medicine

Volumn 335, Issue 5, 1996, Pages 311-315

  Fekade, Daniel ^b   Knox, Kyle ^a   Hussein, Kebede ^b   Melka, Amsel ^b   Lalloo, David G ^a   Coxon, Ruth E ^c   Warrell, David A ^a,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Black Lion Hospital   (Ethiopia)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CHLORPHENIRAMINE MALEATE; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 6; INTERLEUKIN 8; PENICILLIN DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; ANTIBIOTIC THERAPY; ANTIBODY PRODUCTION; ARTICLE; BORRELIA INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; FEMALE; HERXHEIMER REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTENSION; IMMUNOPROPHYLAXIS; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TREATMENT OUTCOME; URTICARIA; VOMITING;

ADOLESCENT; ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; FEVER; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; PENICILLINS; RELAPSING FEVER; SHEEP; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029845610     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199608013350503     Document Type: Article

References (26)

1. Bryceson ADM, Parry EHO, Perine PL, Warrell DA, Vukotich D, Leithead CS. Louse-borne relapsing fever: a clinical and laboratory study of 62 cases in Ethiopia and a reconsideration of the literature. Q J Med 1970; 39:129-70.
2. Warrell DA, Pope HM, Parry EHO, Perine PL, Bryceson AD. Cardio-respiratory disturbances associated with infective fever in man: studies of Ethiopian louse-borne relapsing fever. Clin Sci 1970;39:123-45.
3. Jarisch A. Therapeutische Versuche bei Syphilis. Wien Med Wochenschr 1895;45:721-4.
4. Herxheimer K, Krause. Ueber eine bei Syphilitischen vorkommende Quecksilberreaktion. Dtsch Med Wochenschr 1902;28:895-7.
5. Negussie Y, Remick DG, DeForge LE, Kunkel SL, Eynon A, Griffin GE. Detection of plasma tumor necrosis factor, interleukins 6, and 8 during the Jarisch-Herxheimer reaction of relapsing fever. J Exp Med 1992;175:1207-12.
6. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-55.
7. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229:869-71.
8. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-4.
9. Traccy KL, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteracmia. Nature 1987; 330:662-4.
10. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Mcd 1988; 318:1481-6.
11. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987;1:355-7.
12. Christman JW. Potential treatment of sepsis syndrome with cytokinespecific agents. Chest 1992;102:613-7.
13. Abraham E, Raffin TA. Sepsis therapy trials: continued disappointment or reason for hope? JAMA 1994;271:1876-8.
14. Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Mcd 1990;113:227-42.
15. Exley AR, Cohen J, Buurman WA, et al. Monoclonal antibody to TNF in severe septic shock. Lancet 1990;335:1275-7.
16. Kwiatkowski D, Molyneux ME, Stephens S, et al. Anti-TNF therapy inhibits fever in cerebral malaria. Q J Med 1993;86:91-8.
17. Derkx B, Taminiau J, Radema S, et al. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet 1993;342:173-4.
18. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
19. Butler TC. Relapsing fever: new lessons about antibiotic action. Ann Intern Med 1985;102:397-9.
20. Radolf ID, Norgard MV, Brandt ME, Isaacs RD, Thompson PA, Beutler B. Lipoproteins of Borrelia burgdorferi and Treponema pallidum activate cachectin/tumor necrosis factor synthesis: analysis using a CAT reporter construct. J Immunol 1991;147:1968-74.
21. Butler T, Jones PK, Wallace CK. Borrelia recurrentis infection: single-dose antibiotic regimens and management of the Jarisch-Herxheimer reaction. J Infect Dis 1978;137:573-7.
22. Teklu B, Habte-Michael A, Warrell DA, White NJ, Wright DJ. Meptazinol diminishes the Jarisch-Herxheimer reaction of relapsing fever. Lancet 1983;1:835-9.
23. Smith MB, Hofmann VC. Anaphylactoid reaction to chymopapain. Anaesthesia 1989;44:767-9.
24. Cross AS, Opal SM, Palardy JE, Bodmer MW, Sadoff JC. The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. J Infect Dis 1993;167:112-8
25. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993; 269:1829-35.
26. Spooner CE, Markowitz NP, Saravolatz LD. The role of tumor necrosis factor in sepsis. Clin Immunol Immunopathol 1992;62:S11-S17.